skip to main content

EULAR ACR Myositis Criteria — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMyositisEULAR ACR Myositis CriteriaSCE Rheumatology

Bimekizumab is selected for active radiographic axial spondyloarthritis after appropriate assessment. There is no coexistent plaque psoriasis. Which maintenance regimen matches the UK SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Give bimekizumab 160 mg subcutaneously every 4 weeks

Explanation lettering: E = shown as A · A = shown as E

D is correct. The authorised regimen for both non-radiographic axial spondyloarthritis and ankylosing spondylitis is 160 mg subcutaneously every four weeks. The 320 mg loading and maintenance schedules are psoriasis regimens, while two-weekly dosing is used in hidradenitis suppurativa induction. Improvement should be assessed by week 16 rather than continuing ineffective treatment indefinitely.

Reference: Bimzelx 320 mg pre-filled pen SmPC: https://www.medicines.org.uk/emc/product/100224/smpc